RAPT Therapeutics Inc (RAPT) Options

RAPT under $3

RAPT new 52 week low

RAPT new 52 low

RAPT under $4

RAPT new 52 week

RAPT under $10

Bargin prices!! Lets go!!

RAPT Only 1 Patient had a problem out of 350 people enrolled in the trial

https://finance.yahoo.com/news/1-fda-puts-hold-two-125809258.html Fire sale down here lots of upgrades out last weeK

Surprised that no gap fill occurred prior to results expected near September 12, showing major strength buoyed by estimates of 50.00:

“8:04a ET 5/23/2022 - Benzinga
RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it has initiated its 16-week randomized, double-blind, placebo-controlled Phase 2b clinical trial to further evaluate the efficacy and safety of RPT193 as monotherapy in patients with moderate-to-severe atopic dermatitis (AD).”

12.16 gap fill over the next 14.5 weeks

12.16 gap fill over the next 14.5 weeks

15 weeks to go

8:04a ET 5/23/2022 - Benzinga
RAPT Therapeutics Announces Initiation Of Phase 2b Trial Of RPT193 In Patients With Moderate-to-Severe Atopic Dermatitis

Countdown to potential billions in revenue.

A ton of insider buying last week

Positive sentiment about billions that could be made from Rapt’s drug and pipe financing, perfect storm brewing

It happens,,and more often than not doesn't.
That's why I'd trim, but leave some on the table.

It's way up after hours bud

Can't believe some of you did not take profits near the close.
Greed will kill ya.

Will do

I'll keep n eye out. Let me knoe if u hear something about the price

Supposed to be. There’s no price set on the offering. They just said they’re raising $125M, they could be raising at $50… who knows… but the history has always been lower than the closing price. We will have to wait and see.

This considered dilution?

LOL

https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-announces-proposed-public-offering-common

Most def. Idk how these companies even give a PT like that. Happens way to often and retails get blindsided. I wouldn't even do that if had all the power too.

Offering AH or tomorrow pre

Negative 1,000% plus operating margins. Only Phase 1 still, A long way to go...

Large negative lose percentages across the board on margins.

Only $0.22 revenue per share

Cash flow will burn all money before end of year.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -1,064.70%

Management Effectiveness
Return on Assets (ttm) -27.62%
Return on Equity (ttm) -50.34%

Income Statement
Revenue (ttm) 5.33M
Revenue Per Share (ttm) 0.22
Quarterly Revenue Growth (yoy) 30.70%
Gross Profit (ttm) 5.04M
EBITDA -55.53M
Net Income Avi to Common (ttm) -56.27M
Diluted EPS (ttm) -2.29

Balance Sheet
Total Cash (mrq) 98.41M
Total Cash Per Share (mrq) 3.93
Total Debt (mrq) N/A
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 9.21
Book Value Per Share (mrq) 3.69

Cash Flow Statement
Operating Cash Flow (ttm) -45.66M
Levered Free Cash Flow (ttm) -23.3M

This stock reported legitimate results of its study and is a short squeeze candidate imo if Reddit wanted to wake up to it

Not even 6 months old and already offering??

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It is developing selective small molecules designed to modulate the critical immune responses underlying these diseases. It has discovered and advanced two drug candidates FLX475 and RPT193, which is engaged in targeting C-C motif chemokine receptor 4 (CCR4). Its drug discovery and development engine has identified CCR4 as a drug target that potentially has broad applicability in oncology and inflammatory diseases. Its lead oncology drug candidate FLX475, is designed to selectively inhibit the migration of immunosuppressive regulatory Treg cells into tumors. Its RPT193 drug candidate, is designed to selectively inhibit the migration of type 2 T helper cells (Th2 cells), into allergically-inflamed tissues.

42.00 > hod.

RAPT

29.01 x 30.00

RAPT

Multiple Nasdaq circuit breakers halts today

RAPT

7.7M shares trading float >

RAPT